Newsroom

Miniature TIC
Vidéos

[ANTIBIOGO] Antibiogo : A free diagnostic aid application to counter antibiotic resistance.

Articles

“I have huge respect for our teams in the field who face so many difficulties and danger”, says 3D programm physiotherapist Elise Tauveron on her return from Haiti.

In early 2022, the MSF Foundation launched a research study on its 3D compression mask programme for patients with severe burns in Haiti’s capital Port-au-Prince. Elise Tauveron, who has just spent a month with the teams in Haiti, talks about the launch and significance of the study. In early 2022, the MSF Foundation launched a research study on its 3D compression mask programme for patients with severe burns in Haiti’s capital Port-au-Prince. Elise Tauveron, who has just spent a month with the teams in Haiti, talks about the launch and significance of the study.

Read more
Événements

The MSF Foundation will be present at Vivatech from June 15 to 18

The MSF Foundation will be at Viva Technology 2022 - June 15 to 18 in Paris. You will find Antibiogo on the Google.org booth.

Read more
App Antibiogo
Articles

After 5 years of development, Antibiogo becomes the first medical device with CE marking developed by the MSF Foundation!

Read more
Événements

Meet the MSF Foundation at the Nancy burns congress from June 8 to 10

The MSF Foundation will be present at the 41st Congress of the Société Francophone de Brûlologie at the Centre Prouvé in Nancy to talk about the 3D Program.

Read more
Événements

Discover the work of the MSF Foundation at ChangeNow

At ChangeNow, on Friday, May 20 at 10 a.m., Dr. Nada Malou will present Antibiogo in the "Big Innovations that will change Health" session.

Read more
Articles

Nezabutni, an innovative platform to help the most vulnerable Ukrainians amidst war

Nezabutni Charitable Foundation with support of The MSF Foundation has launched an initiative to help Ukrainian people with dementia and elderly people in times of war. Irina Shevchenko and Natalie Roberts, who met in Ukraine a few weeks ago, explain the situation on the field and the major challenges for vulnerable people in the country now, which the platform created by Nezabutni addresses.

Read more

Headline

MSF Foundation in Video

  • Officially launching of Antibiogo : Webinar
    Vidéos

    Officially launching of Antibiogo : Webinar

  • AdreUne
    Vidéos

    Report from Adre in Chad, where MSF Foundation teams explore the needs for pediatric rehabilitation.

  • YemenUne_en
    Vidéos

    Reportage in Haydan, Yemen, on the development of the rehabilitation care in the MSF sites.

News

  • Articles

    Antibiogo: facts and impacts in the fight against antimicrobial resistance

    The World Health Organization's Global AMR Awareness Week is a worldwide campaign to raise awareness and understanding of the problem of antimicrobial resistance. To mark the occasion, here is a series of infographics to help you better understand the hope that Antibiogo, a new diagnostic tool holds for combating this threat on public health.

    Read more
  • Articles

    Cervical cancer : when AI helps improve diagnosis

    Cervical cancer is the second deadliest cancer in low- and middle-income countries (1). In Malawi in East Africa, where MSF operates, over 4,000 Malawian women fall sick with cervical cancer every year. With 2,905 deaths due to cervical cancer in 2020, the country also had the second highest rate of mortality (2). How can we explain such a high mortality rate from this disease which, in high-income countries, is easily preventable and generally less deadly?  The reasons include limited access to prevention and screening, and diagnoses that are not always reliable.

     

    Clara Nordon, Director of the MSF Foundation, has just got back from a visit to Malawi with the MSF teams and tells us about the project led by the Foundation. Code name: AI4CC

    Read more

Publications

  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more

Press Review

No news for now.